{"prompt": "['2017N330177_04', 'CONFIDENTIAL', '205678', 'os', 'PFS', 'Study Assessments', 'EOT Visit\u00b9', 'Follow-', 'Notes', 'Follow-up\u00b2', 'Up\u00b3', 'Bone marrow biopsy to', 'Only if CR has been achieved', 'Only if CR have been', 'for extramedullary disease as clinically indicated.', 'assess sCR by IHC16', 'on this visit', 'achieved on this visit', 'Biomarkers', '13. Germany: no PET/CT to confirm CR or sCR will be performed until', 'approved by the German Federal Office of Radiation Protection until', 'Soluble BCMA (serum)', 'X', 'further notice.', 'cfDNA (plasma)', 'X', 'Optional', '14. Only required for participants with lgD/E myeloma, where serum m-', 'Optional tissue sample', 'component cannot be followed otherwise.', 'At time of PD', 'At time of PD', 'at PD for BCMA17', '15. Performed by a central lab at the time of first achieving VGPR or CR. And', 'Health Outcomes', 'repeated at 6 months and 12 months after achieving the VGPR or CR', 'PRO-CTCAE', 'X', '(provided VGPR/CR is maintained).', 'NEI-VFQ-2518', 'X', 'X', 'X', '16. In participants achieving a CR, bone marrow biopsy to confirm sCR by', 'OSDI18', 'X', 'X', 'IHC.', 'EORTC-QLQ-C30', 'X', 'EORTC-QLQ-MY20', '17. Upon PD- Optional tumor sample (BM aspirate clot, or fresh tissue, or', 'Patient Interview (PRO)', 'tissue block from extramedullary tumor) for BCMA expression analysis by', '19', 'IHC. To be submitted to central lab for analysis', 'Survival Status phone', 'X', '18. Participants who discontinue participation in the study will continue to be', 'call', 'assessed during follow-up until resolution of visual symptoms. Continue', 'to follow up with participants via telephone who are still experiencing', 'visual symptoms even after discontinuation', 'Subsequent Treatment', 'X', 'X', '19. Patient Interview (PRO) must be conducted via telephone within 21 days', 'Information', '(+7 days) of the end of treatment visit, unless the participant has already', 'completed their interview following C4D1 within the prior 30 days.', 'Abbreviations:', 'BM = bone marrow; BP = blood pressure; cfDNA = Circulating free DNA; CRP = C-reactive protein; EORTC QLQ-C30 = European Organization for Research and Treatment of Cancer', 'Quality of Life Questionnaire 30-item Core module; EORTC QLQ-MY20 = European Organization for Research and Treatment of Cancer Quality of Life Questionnaire 20-item Multiple', 'Myeloma module; FISH = fluorescence in situ hybridization; FLC = free light chain; ; HR= heart rate; Ig = immunoglobulin; NEI-VFQ-25 = National Eye Institute Visual Functioning', 'Questionnaire 25; OSDI = Ocular Surface Disease Index; PRO-CTCAE = Patient Reported Outcome version of the Common Term Criteria for Adverse Events; PD = Progressive', 'Disease; PK = Pharmacokinetics; SPEP = serum protein electrophoresis; UPEP = urine protein electrophoresis.', '31']['2017N330177_04', 'CONFIDENTIAL', '205678', 'Table 4', 'Ocular Sub-Study Schedule of Activities (Selected Sites Only)', 'C1-C4', '10 days', 'Cycle 1-', 'Every 3 weeks starting at week 4 (to be completed', 'C5-', 'End of', 'PFS', 'os Follow-', 'Study Assessments', 'Screen', 'post', 'Cycle 4', 'regardless of dose given)', 'CX', 'Treatment', 'Follow-up', 'up', 'Dose', 'exam', 'Informed Consent', '1', 'X', 'Steroid eye drops 2', 'X', 'X6', 'Preservative-free artificial', 'X3', 'X3', 'X3', 'X3', 'tears 3', 'Full Ocular exams 1,4', 'X', 'X', 'X', 'X6', 'X', 'X6', 'X6', 'Specialty Ocular Exams1,', 'X', 'X', 'X', 'X', '5,6', '1.', 'Informed consent obtained for inclusion into the ocular sub-study population. Consent must be obtained prior to performing any sub-study protocol-related procedures. All', 'Screening assessments must be performed within 21 days prior to first dose unless otherwise specified. There is no need to repeat screening ocular', 'assessments', 'at', 'C1D1', 'if', 'they', 'have been done within 21 days of first dose.', '2.', 'Steroid eye drops administered as prophylaxis (such as: prednisolone acetate 1.0%, prednisolone phosphate 1%, dexamethasone 0.1%, or equivalent) 1 drop QID starting 1 day', 'prior to each GSK2857916 infusion, and continuing for a total of 7 consecutive days. Steroid eye drops are to be administered in only one eye as assigned (randomized) centrally', 'by the Sponsor and the site staff will instruct the participant which eye will be treated. The ophthalmologist will remain blinded to this decision. The treating ophthalmologist has', 'discretion to begin steroid drops in the both eyes should the participant develop symptoms requiring intervention as clinically indicated. Intraocular pressure should be monitored', 'if', 'steroid eye drops are used for more than 7 consecutive days.', '3.', 'Prophylactic preservative-free artificial tears will be administered starting 1 day prior to C1D1 according to Section 9.2.10.1. Outside of the 7-day prophylaxis period they should', 'be administered at least 4-8 times daily as needed, at least one drop in each eye, until end of treatment or as clinically indicated.', '4.', 'Participants will undergo \"full\\' ocular exams as outlined in Section 9.2.9 within 3 days prior to day 1 and on day 10 (+3 days) of Treatment Cycles 1, 2, 3 and 4 (4 doses of study', 'medication). Day 10 exam is only necessary after participant receives study medication.', \"5. Participants could undergo 'specialty' ocular exams as outlined in Section 9.2.10 on Day 10 (+3 days) of Treatment Cycles 1, 2, 3 and 4 (4 doses of study medication) and within 3\", 'days prior to day 1 of cycles 2,3, and 4. A Day 10 exam is only necessary if participant receives study medication.', '6.', 'After Cycle 4 Day 10, participants who have no signs/symptoms should revert to the ocular activities of the general participant population (see main SOA tables), treatment with', 'steroid eye drops, and specialty ocular exams should continue at the discretion of the treating ophthalmologist. If a participant subsequently develops ocular signs/symptoms, or', 'they require additional treatment, participant must be evaluated by an ophthalmologist (an optometrist if an ophthalmologist is not available), and treated as clinically indicated.', '32']\n\n###\n\n", "completion": "END"}